Peter Lio, MD

Panelists discuss the frequency of combination therapy use in managing atopic dermatitis, highlighting its role in enhancing treatment efficacy and addressing multifactorial aspects of the disease in their patient population.

Panelists discuss when to consider switching to another biologic or exploring a different mechanism of action in atopic dermatitis treatment, focusing on factors like inadequate response, adverse effects, or the need for more targeted therapy to optimize patient outcomes.

Panelists discuss the maintenance of treatment efficacy in the lebrikizumab clinical trial, highlighting data on sustained improvement in atopic dermatitis symptoms over time and the long-term effectiveness of the treatment.

Panelists provide an overview of the latest efficacy and safety data for IL-13–targeting therapies in atopic dermatitis (AD), including recently presented data on dupilumab, lebrikizumab, and tralokinumab, focusing on their effectiveness in symptom reduction and safety profiles across patient populations.

Panelists discuss the differences between the 3 FDA-approved IL-13–targeting agents for atopic dermatitis (AD)—dupilumab, tralokinumab, and lebrikizumab—and how these differences in their mechanisms of action might impact their effectiveness in targeting the disease and addressing various patient needs.

Panelists discuss recent guideline changes regarding advanced systemic therapy in atopic dermatitis (AD), focusing on when to transition a patient to systemic agents and when biologics should be considered for the treatment of moderate to severe AD.

Panelists discuss how treatments for atopic dermatitis impact patients' quality of life, focusing on improvements in symptoms, daily functioning, and emotional well-being with different therapeutic options.

Panelists discuss how the standard of care in atopic dermatitis (AD) has evolved with recent advances in treatment, highlighting the use of assessment tools and scoring systems in clinical practice, and compare real-world outcomes with those seen in clinical trials for AD treatments.

Panelists discuss how recent treatment approvals for atopic dermatitis (AD), including new biologics and systemic therapies, are reshaping management, and emphasize how patient factors, such as severity, comorbidities, and treatment history, guide treatment selection in AD.

Panelists discuss how to confirm the diagnosis of atopic dermatitis (AD) when in doubt, emphasizing the importance of clinical evaluation, family history, and skin testing, and share strategies for approaching adult patients with new-onset AD, including thorough patient history and targeted management.

Panelists discuss how the clinical heterogeneity of Atopic Dermatitis (AD) presents diagnostic challenges, with varying criteria for pediatric and adult-onset AD, highlighting the need for age-specific approaches to accurately diagnose and treat the condition.

Medical experts share their final thoughts on the future of atopic dermatitis treatment with oral systemic agents.

Medical experts review the data on the use of oral JAK inhibitors for maintenance and rescue treatments in atopic dermatitis.

Medical experts discuss how often patients with atopic dermatitis request treatment breaks, their monitoring approach during these breaks, and how to educate and counsel patients about treatment breaks and rescue treatments, including identifying suitable candidates.

Medical experts rate dermatologists’ comfort with switching to JAK inhibitors and describe how frequently to switch patients from biologics to JAK inhibitors, including their treatment strategy for this population.

Medical experts discuss disease control with abrocitinib or upadacitinib in patients previously taking dupilumab and explain the circumstances under which they would switch a patient to a JAK inhibitor.

Medical experts discuss the importance of setting treatment expectations and maintaining dialogue with patients about targets and explain how to decide on a new treatment when switching.

Medical experts evaluate the role of biologics in atopic dermatitis, including their efficacy and safety, and discuss reasons for switching between systemic treatments.

Medical experts discuss the significance of speed in achieving itch relief when choosing a treatment for atopic dermatitis.

Medical experts review and comment on the effectiveness of oral JAK inhibitors in providing itch relief for patients with atopic dermatitis.

Medical experts discuss long-term data for other systemic agents in atopic dermatitis and how this information informs their treatment decisions.

Medical experts review phase 3 and long-term efficacy and safety data for abrocitinib and upadacitinib in atopic dermatitis and discuss how these data influence treatment decisions and any ongoing safety concerns.

Medical experts discuss the patient screening process for oral JAK inhibitors and identify absolute or relative contraindications.

Medical experts review the FDA-approved oral JAK inhibitors for atopic dermatitis (abrocitinib, upadacitinib), highlighting differences from conventional therapies, their appeal, and the criteria for recommending them based on disease severity and patient characteristics.

After a brief introduction, medical experts review the pathophysiology of atopic dermatitis and explain how JAK inhibitors modulate this inflammatory condition.

Expert providers in inflammatory diseases provide additional resources on biosimilars and adalimumab biosimilar for patients and providers.

Providers in inflammatory diseases discuss the instrumental role nurses and support staff play in educating patients on adalimumab biosimilars.

Drs Lio, Botsoglou, and Alexrad discuss the most asked questions and common concerns patients have on adalimumab biosimilars.

Clinicians and a pharmacist discuss how they are managing access and assistance with copay assistance program in their practices.

Healthcare providers in inflammatory diseases talk about the role they have on encouraging adalimumab biosimilar use in clinical practice.